Menu
Menu
We’re excited to announce that Hospital Arnau de Vilanova de Valencia—one of Spain’s premier academic health science centers—has expanded its collaboration with SOPHiA GENETICS. The team is now harnessing the capabilities of the SOPHiA DDM™ Community Myeloid Solution—our DNA-only, multimodal-ready application—to support deeper, more actionable insights in the analysis of myeloid malignancies. This expanded partnership reinforces […]
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced an expanded collaboration with Result Laboratorium, a leading clinical laboratory in the Netherlands, to advance the delivery of pharmacogenomics (PGx) insights across the region using the SOPHiA DDM™ Platform and SOPHiA DDM™ Dispatch. By centralizing sequencing and analysis […]
We are thrilled to welcome Atrys Health to our network. Based in Lugo, Atrys Health is an established genetics reference centre in Spain. The team will leverage the SOPHiA DDM™ Solid Tumor application to strengthen their solid tumor profiling capabilities. This partnership reinforces Atrys Health’s dedication to more accurately assessing key biomarkers essential for solid […]
Exciting news! We are thrilled to welcome Amrita Hospital to our network. Based in Faridabad, India, Amrita Hospital is recognized as one of the premier healthcare institutions. The hospital improves the well-being of the local community through initiatives aimed at providing outstanding and affordable medical care in the spirit of compassion to all. The hospital […]
Abu Dhabi, United Arab Emirates; June 3, 2025: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and […]
We’re proud to announce that Bioma Genetics, a leading precision medicine center in Brazil, has expanded its partnership with SOPHiA GENETICS by adopting the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. This advanced application enables the accurate identification of HRR gene mutations and genomic instability, providing researchers with comprehensive insights into HRD status. By integrating this […]
BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount […]
BOSTON, MA and ROLLE, Switzerland, April 28, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October […]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.